Catalysts / KARD
Upcoming FDA decisions and readouts we track for Kardigan, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Kardigan (KARD, listed on Nasdaq). They cover 3 programmes: Danicamtiv (Genetic dilated cardiomyopathy), Ataciguat (Calcific aortic valve stenosis (interim 24-week analysis)) and Tonlamarsen (Acute severe hypertension).
First on the list: the Phase 2B readout for Danicamtiv (Genetic dilated cardiomyopathy), guided by the company to H1 2027. The furthest-out event tracked is H1 2027. By stage, the upcoming rows are 1 Phase 2 readout and 2 Phase 2B readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Kardigan KARD · Nasdaq | Danicamtiv | Genetic dilated cardiomyopathy | H1 2027 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Kardigan KARD · Nasdaq | Ataciguat | Calcific aortic valve stenosis (interim 24-week analysis) | H1 2027 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Kardigan KARD · Nasdaq | Tonlamarsen | Acute severe hypertension | H1 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList